Proteomics, pathway array and signaling network-based medicine in cancer
- David Y Zhang1Email author,
- Fei Ye1,
- Ling Gao2,
- Xiaoliang Liu2,
- Xin Zhao3,
- Yufang Che4,
- Hongxia Wang5,
- Libo Wang6,
- Josephine Wu1,
- Dong Song7,
- Wei Liu8,
- Hong Xu4,
- Bo Jiang4,
- Weijia Zhang9,
- Jinhua Wang10 and
- Peng Lee11Email author
© Zhang et al; licensee BioMed Central Ltd. 2009
Received: 16 September 2009
Accepted: 28 October 2009
Published: 28 October 2009
Cancer is a multifaceted disease that results from dysregulated normal cellular signaling networks caused by genetic, genomic and epigenetic alterations at cell or tissue levels. Uncovering the underlying protein signaling network changes, including cell cycle gene networks in cancer, aids in understanding the molecular mechanism of carcinogenesis and identifies the characteristic signaling network signatures unique for different cancers and specific cancer subtypes. The identified signatures can be used for cancer diagnosis, prognosis, and personalized treatment. During the past several decades, the available technology to study signaling networks has significantly evolved to include such platforms as genomic microarray (expression array, SNP array, CGH array, etc.) and proteomic analysis, which globally assesses genetic, epigenetic, and proteomic alterations in cancer. In this review, we compared Pathway Array analysis with other proteomic approaches in analyzing protein network involved in cancer and its utility serving as cancer biomarkers in diagnosis, prognosis and therapeutic target identification. With the advent of bioinformatics, constructing high complexity signaling networks is possible. As the use of signaling network-based cancer diagnosis, prognosis and treatment is anticipated in the near future, medical and scientific communities should be prepared to apply these techniques to further enhance personalized medicine.
List of abbreviations
single nucleotide polymorphism
copy number variations (CNV)
Differential in Gel Electrophoresis (DIGE)
matrix assisted laser desorption/ionization
surface-enhanced laser desorption ionization
Analysis of Microarrays
Cancer Signaling Network
Cancer is a complex disease that results from complex signaling network pathway alterations that control cell behaviors, such as proliferation and apoptosis. The complexity of signaling network is multidimensional given the exceedingly high number of components (i.e. nodes and hubs), multiple connections (i.e. edges) between pathways (i.e. cross-talk) and many feedback loops (i.e. redundancy and compensation) . Furthermore, the components in each signaling network operate at different spatial and temporal scales with continuous, dynamic changes in response to cell-cell and cell-stromal interactions. This complex, dynamic signaling network collectively affects cell function and behaviors with the possibility of sub-network (or module) affecting different function or behavior. Therefore, this multidimensional complexity poses a great challenge in network biology research.
Understanding signaling networks involved in carcinogenesis significantly advances our knowledge of cancer initiation and progression, including metastasis. Signaling network alterations accumulate at each stage of carcinogenesis that results from genetic, epigenetic and environmental changes and is viewed as a multi-step model of carcinogenesis . Furthermore, the specific signaling networks that reflect the hallmarks of cancer have been demonstrated and include the ability to mimic normal growth signaling, insensitivity to antigrowth signals, ability to evade apoptosis, limitless replicative potential, sustained angiogenesis, and tissue invasion and metastasis [1, 3].
Signaling network research is also important in diagnosis, biomarkers, cancer progression, drug development and treatment strategies. Recently, several studies have demonstrated the feasibility of cancer signaling network-based approaches for cancer diagnosis, prognosis and therapy . In this paper, we will review the latest advancements and current progress in cancer signaling network research.
Genomic Based Approaches For Signaling Network
The ability to collect data from a large number of genes in the same sample, including gene expression and DNA alterations, opens the possibility of obtaining network-level data. Currently, the signaling network information is typically derived from genomic profiling studies including gene expression, single nucleotide polymorphism (SNP), copy number variations (CNV) and DNA methylation (see Additional file 1) [5–12]. A limitation of genomic profiling studies is that mRNA levels and DNA alterations may not accurately reflect the corresponding protein levels and fail to reveal changes in posttranscriptional protein modulation (e.g., phosphorylation, acetylation, methylation, ubiquitination, etc.) or protein degradation rates . More importantly, the signaling network constructed using these approaches does not reflect the dynamic signal flow in a spatial relationship. On the other hand, the genomic changes (mRNA level, SNP, CNV, methylation) ultimately affect protein expression, activation and inactivation, which, in turn, controls cellular behavior. Therefore, the use of a proteomics approach that can add protein-protein and protein-DNA information, which more accurately reflects the signal flow and dynamic change in the signaling network and could be a valuable addition to genomic profiling studies.
Challenges of Protein-Based Approaches
The major challenge of proteomic research is the limited assay sensitivity of analyzing cell proteins. Although each mammalian cell contains approximately 30,000 genes, the proteins coded by these genes can be as many as 200,000 to 300,000 due to alternative splicing. Furthermore, the proteins involved in cellular homeostasis, metabolism and structure are abundant and are present 10,000 to 100,000 fold greater than proteins involved in signaling networks in an individual cell. Therefore, detection and quantification of these cell signaling proteins poses a great challenge. Two dimensional gel electrophoresis (2D) or liquid chromatograph (LC) in combination with mass spectrometry (MS) is a widely used technology to identify proteins. An important advantage of these sensitive techniques is the ability to identify unknown proteins in a complex sample. However, costly instrumentation is typically required and often insufficient to detect proteins that are in low abundance.
On the other hand, antibody detection offers great sensitivity and specificity to detect known proteins in a sample. However, multiplex array, i.e. protein arrays, to identify proteins with antibodies also has limitations. For example, capture molecules are proteins themselves and tend to denature with changes in pH or temperature. Furthermore, antigen-antibody interactions are determined by complex associations between epitope sites on the target protein and the antigen-binding site on the antibody, which are both influenced by external conditions. Antibodies must exhibit strong affinities and specificity for each respective substrate, particularly when investigating the activated state of specific proteins, such as phosphorylation, glycosylation or proteolytic cleavage. Subsequently, activation-specific antibodies, routinely used in Western blots, may not be suitable in an array format, as the phosphorylation-specific site may be imbedded within the interior aspect of protein and inaccessible to the antibody.
Quantifying protein concentration represents another problem when analyzing hundreds of antibody-antigen interactions in a single array as each antibody-antigen pair possesses an independent affinity constant. However, the variation in protein concentrations in cells may be as high as 6 folds. Thus, detection methods must be developed to quantify protein concentrations over many orders of magnitude. The detection of antigen-antibody pairs is routinely performed by either sandwich assays in which two complementary antibodies to different sites of the protein are used, or by detecting a label on the protein itself. Conjugation of proteins may disturb the native folding structure of proteins and thus may destroy the antibody-antigen interaction, yielding false negatives.
Proteomics-Based Techniques for Cancer Signaling Network Research
Although protein-based techniques such as 2D gel, MS and antibody-antigen assays have long been available, the application in clinical research is limited (see above). However, during the past decade, the technologies have significantly improved and have rapidly transitioned to the clinical laboratories. The techniques can be categorized into two groups: MS-based and antibody-based technologies (see Additional file 2). This section discusses the most commonly used protein detection techniques as well as computational methods for data analysis and network simulation.
Detection of unknown proteins by two dimensional gel electrophoresis and mass spectrometry
Recently, a modified 2D protein electrophoresis technique, Differential in Gel Electrophoresis (DIGE), was developed to monitor differences in the proteomic profile of two separate samples. In this method, 2-3 paired samples can be run on the same 2D gel after labeling with each cyanine dyes (Cy2, Cy3 and Cy5). After completing the 2D electrophoresis, the proteins in each sample are detected by a phosphorimager with different fluorescent channels. The different fluorescent images of the same gel are superimposed to identify and quantify differentially expressed proteins. This approach reduces experimental variation, increases quantification accuracy and improves the sensitivity of the technique. The differentially expressed protein spots are then excised from the gel, digested to fragments and identified by MS.
Peptide fragments derived from 2D gel electrophoresis (as well as liquid chromatography) is a precursor to mass spectrometry (MS), a process that identifies the ratio of elemental and isotopic components in a given sample (Figure 1). The principle of MS is that the molecules or proteins in the sample are ionized from the solid to gaseous phase via an ion source. The ions are then separated from each other based on their mass-to-charge (m/z) ratios in the mass analyzer. Finally, the ions are detected, the abundance of each ion is calculated and the structure of the protein is determined by comparing the database against a known protein sequence database . In the past decade, MS has significantly advanced, including improved ionization (matrix assisted laser desorption/ionization (MALDI), electrospray ionization (ESI), surface-enhanced laser desorption ionization (SELDI)) and more sensitive mass analyzers (time-of-flight (TOF), ion trap, and quadrupole). The combination of these systems offers a higher sensitivity (femtomole or picogram), resolution and mass accuracy. In the future, high through-put identification of proteins, broad dynamic range of quantification (104 to 105) and characterization of post-translational protein modifications will be possible.
Detection of known proteins with protein microarray
Protein microarray technology is a powerful emerging analytical strategy for interrogating the proteomes of tissues and cells. As a high-throughput screening platform, protein microarray permits rapid quantitative identification of cancer biomarkers associated with oncogenesis and disease progression. Protein microarray can accelerate the current understanding of cellular differentiation, transformation, angiogenesis, tumorigenesis, and metastasis. This new technology has the ability to 1) quickly elucidate alterations in protein expression levels, 2) detect post-translational modification and mRNA processing events, and 3) dissect molecular networks associated with drug administration or exposure to environmental factors (for example, toxins, infectious agents, or radiation). With the advent of protein microarrays, global profiling cancer signaling network diagnosis and prognosis as well as personalized therapy becomes possible. There are several different types of protein arrays, including reverse phase protein array, antibody array, etc  that may be performed on several supporting platforms, including glass slides, membranes, and beads.
Reverse phase protein arrays are used to profile dozens or hundreds of samples (research or clinical) for the presence of a small number of antigens (Figure 2A). Cell lysates, material from laser capture microdissection, or serum samples are arrayed. This creates an array of "unknowns" that can be probed with a small number of antibodies. Visualization can be performed with a detection antibody linked to a fluorophore or color detection reagent .
Antibody arrays and Microspot ELISA are used for quantitative profiling of protein expression in cells and clinical samples (Figure 2B). Typically these arrays are low-density (9-100 elements/array). However, the density of the antibody array is expected to increase and will continue to expand due to the availability of a large number of high affinity antibodies. In these arrays, known antibodies are arrayed and used to capture antigens from unknown samples. To detect an antigen that is bound to the array, the antigen is labeled directly with a fluorophore or a second binder/antibody . The latter option creates a sandwich assay similar to a traditional ELISA, but in a microspot format. Thus, the term "microspot ELISA" is used.
Bead-based array is a potentially powerful complement to planar arrays. The Luminex bead array system is increasingly used in protein profiling applications (Figure 2C) . The system uses multiple, different fluorescent beads that are spectrally distinguishable and coated with a different capture antibody. The beads are incubated with a sample to allow protein binding to the capture antibodies. The mixture is incubated with a mixture of detection antibodies, each corresponding to one of the capture antibodies. The detection antibodies are tagged to allow fluorescent detection. The beads are passed through a flow cytometer and each bead is probed by two lasers: one to determine the identity of the bead based on the bead's color and another to read the amount of detection antibody on the bead.
Pathway Array is an innovative, powerful tool to analyze the expressed proteins with excellent sensitivity and specificity. This is an immunoblot-based assay and was recently developed and validated in the authors' laboratory . It allows for global screening of changes in protein expression and post-translational modification (i.e. phosphorylation). The focus of the Pathway Array is to determine the signaling network that controls cancer development (initiation, promotion, progression and metastasis). The proteins selected for study in the array are highly expressed in cancer cells and are functionally linked to angiogenesis, apoptosis, cell cycle regulation, DNA repair, migration, proliferation, signaling, stem cell association and transcription activity (see Additional file 3).
Pathway Array assay has several important features. The coverage of signaling network-related proteins is high with at least one representative protein (typically 2-3) included for each pathway (see Additional file 3). The selection of antibodies was based on previously described functionality in the literature, the Human Protein Atlas http://www.proteinatlas.org/ and commercial availability. It is estimated that approximately 500 genes code for kinases, 1,500 genes code for transcription factors, 400 genes code for G-protein-coupled receptors and 1,200 genes code for candidate cancer biomarkers . Currently, approximately 6,000 antibodies are commercially available, which accounts for nearly 25% of all 21,528 predicted human genes .
Computational Methods For Proteomic Array Data Analysis
Currently, a bioinformatic method specifically designed for high density protein expression array analysis is unavailable. However, some statistical tools developed for genomic microarray can be used for protein arrays. Examples of statistical tools that can be used for protein arrays are listed below.
BRB-Array Tools is an integrated software package for the analysis of genomic microarray data http://linus.nci.nih.gov/BRB-ArrayTools.html. BRB-Array Tools is an add-on to Excel and provides an user friendly platform to perform ANOVA functions, cluster genes and samples, functional and predictive sample classifications, and data visualization tools . The package is very portable and has unrestricted use with any particular array platform, scanner, image analysis software or database. BRB-Array Tools identifies differentially expressed genes across groups (also referred to as "Class Comparison") using reliable statistical methods designed to better manage the false discovery rate (FDR). It also constructs and evaluates multivariate predictors for classifying unknown samples into groups based on gene expression profiles (also referred to as "Class Prediction"). For protein expression array analysis, the data set of protein expression signal intensities can be imported to BRB-ArrayTools in an Excel format. The computations are performed by sophisticated statistical tools external to Excel, including ANOVA for identification of genes differentially expressed amongst the groups (two or more groups) and t-test or F-test (paired groups). The outputs are gene rank lists based on statistical tests and figures based on visualization tools, including heat map and Multi-Dimensional Scaling which reduces high dimensional data to graphical displays. We have successfully applied BRB-Array Tools for our Pathway Array data analysis (see next section).
Prediction Analysis of Microarrays (PAM) is a statistical technique for class prediction and survival analysis from gene expression data using nearest shrunken centroids http://www-stat.stanford.edu/~tibs/PAM/ (Figure 6B). The method of nearest shrunken centroids identifies subsets of genes that best characterizes each class . The technique is general and can be used in many other classification problems. For survival outcomes, PAM uses prediction by the 'supervised principal components' method. PAM incorporates reliable statistical methods designed to better manage the FDR. PAM estimates prediction error via cross-validation and provides a list of significant genes whose expression characterizes each diagnostic class. The data from cDNA and oligo microarrays, protein expression data and SNP chip data can used for PAM analysis.
Signaling network construction
Although computational modeling platforms will soon become standard tools in constructing signaling networks for clinical applications, comprehensive tools are still not presently available. To establish 2-dimensional or even 3 -dimensional signal signaling networks in cancer cells requires the integration of mathematical, computational, biology and clinical sciences. The data available from genomic, proteomic and biochemical experiments creates a framework for signaling network construction. Furthermore, the integration of data from of other genomic studies included mRNA expression, SNP, CNV, methylation etc. is necessary to establish a comprehensive signaling network.
Several computer programs are available for simple prediction of signaling network and graphic presentation. Weighted Co-expression Analysis is used to explore molecular interaction networks across RNA expression in different samples in microarray datasets . In this model, the network construction is based on the concept that nodes represent genes and nodes are connected if the corresponding genes are significantly co-expressed across appropriately chosen tissue samples. The co-expression networks can be organized into modules of system level functionality for coordinated gene expression. Category analysis and Gene set enrichment analysis (GSEA) provide pathway enrichment tools to help interpret datasets . This approach designed to detect the categories, or sets, of genes where there are potentially small but coordinated changes in the expression of groups of functionally related genes. Ingenuity Pathway Analysis, a commercial software, provides a link to database derived from literature to find function and pathways for microarray analysis http://www.ingenuity.com/products/pathways_analysis.html. Ingenuity Pathway Analysis is an web-based application that enables users to analyze, integrate, and understand data derived from gene expression, microRNA, SNP and proteomic microarray . The capabilities of Ingenuity Pathway Analysis are to: 1) rank the genes and proteins in a dataset according to the characteristics that make a gene product a biologically plausible candidate biomarker; 2) measure whether a particular gene or protein is detectable in sentinel tissues (e.g., blood, bone marrow), urine and other bodily fluids; 3) select parameters that are most relevant to a biomarker discovery project; 4) elucidate mechanisms linking potential markers to the disease or biological process of interest; and 5) generate a list of candidate markers unique to one treatment or disease, or common across all treatments.
Some existing signaling network databases are also available including KEGG pathway http://www.genome.jp/kegg/pathway.html and BioCarta pathways http://www.biocarta.com/genes/allpathways.asp. These networks were constructed based on published literature and databases, such as Entrez Gene http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db_gene and Gene Ontology, which provide molecular function, biological process and cellular location. Gene Ontology is a major bioinformatics initiative that aims to standardize the representation of gene and gene product attributes across species and databases http://www.geneontology.org/GO.tools.shtml. The project provides a controlled vocabulary of terms for describing gene product characteristics and gene product annotation data from GO Consortium members, as well as tools to access and process this data.
Research and Clinical Applications for Pathway Array
The Pathway Array has broad applications in translational research and clinical utilities, including discovering diagnostic and prognostic biomarkers, identifying novel therapeutic targets, and providing tools for future personalized therapy. The following are examples of Pathway Array applications in different cancers.
Discovery of diagnostic biomarkers
Discovery of prognostic biomarkers
Most studies that predict non-small cell lung cancer survival used a genomic microarray platform. For example, Chen et al showed that 16 genes from an initial microarray study and risk score analysis correlated with survival among patients with NSLC . The authors subsequently selected five genes (DUSP6, MMD, STAT1, ERBB3, and LCK) for RT-PCR and decision-tree analysis. The five-gene signature was an independent predictor of relapse-free and overall survival. Fan et al. showed that a 13 gene profile associated with the vascular endothelial growth factor (VEGF) subnetwork, including VEGF, ANGPTL4, ADM and the monocarboxylic acid transporter SLC16A3, can predict distant metastasis and poor outcomes . These results suggest that activation of certain signaling network may correlate with a poor prognosis.
Discovery of potential therapeutic targets
Hepatocellular carcinoma (HCC) is the fifth most common malignancy and the third leading cause of cancer death in the world, with the five-year survival rate approaching 7% . Treatments of HCC include surgical resection and transplantation, ablation and transarterial chemoembolization, and systemic chemotherapy [34, 35]. However, except for surgical resection/transplantation of early stage HCC, the survival time is not significantly prolonged by any of these treatments. Therefore, development of newer therapeutic targets for HCC treatment is urgently needed.
We studied 10 tumor tissues and paired non-tumor tissues from 10 hepatitis-related HCC patients. Among the 44 antibodies tested, 23 proteins and phosphoproteins were detected and 22 had a more than 2-fold change between the cancerous and normal tissues. Of these proteins, XIAP and CDK6 were highly expressed in tumors as compared with surrounding tissues (54% and 46% tumors, respectively). XIAP is a member of the IAP family (inhibitor of apoptosis), which inhibits a subset of caspases (i.e. caspase 3 and 9). CDK6 activates cyclin D1 and the cyclin D1/CDK6 complex activates pRB and E2F which controls the cell cycle progression from the mid-G1 to S phase. Therefore, increased expression of XIAP and CDK6 in HCC may result in decreased apoptosis and increased cell proliferation.
In order to determine if XIAP and CDK6 can be therapeutic targets, we applied siRNA technology to silence the expression of XIAP and CDK6 in HCC cells. Our results showed a significant reduction in cell viability by both XIAP and CDK6 specific siRNAs and the cause of cell death was necrosis (i.e. PI positive cells) rather than apoptosis (Annexin positive cells) (see Additional file 4). These results indicate that both XIAP and CDK6 are important for HCC cell survival. We further tested that small molecules specific for these targets, including embolin for XIAP and flavopiridol for CDKs. Both molecules showed a significant inhibition of HCC cell growth, suggesting that both XIAP and CDK6 can be potential targets for HCC treatment.
Detection of signaling activities for personalized therapy
Currently, the treatment of most cancers is based on the tissue types and clinical stages. This approach is often ineffective due to the heterogeneity of the tumors. Recently, the use the signaling network approach to break down complex oncogenic signaling networks into basic units, or modules, of signaling activity (e.g., a protein phosphorylating another protein to activate its kinase activity) and demonstrate that gene expression signatures based on these modules can predict the effectiveness of pathway-specific therapeutics .
As stated above that current systemic chemotherapy for HCC is ineffective [34, 35]. A recent study showed that targeted therapy with molecules, such as sorafenib which inhibits multiple tyrosine kinase receptors (RAS/VEGFR) , may offer some benefit with this deadly disease (~3 months improvement of survival). A reason for the limited benefit of signal pathway based treatment is the redundancy and compensation of the signaling network in HCC. Our recent study showed inhibition of XIAP and CDK6 reduced HCC cell proliferation. However, a significant reorganization of the signaling network observed, including down regulation of tumor suppressors (p-p53 and CHK1 when XIAP silenced or p-RB when CDK6 silenced) and upregulation of tumor promoting proteins (ETS1 when XIAP silenced or p-CREB when CDK6 silenced), which may confer the growth benefit for cancer cells. Therefore, it is conceivable that inhibition of a main pathway and an associated compensatory pathways, the efficacy of chemotherapy will be significantly improved.
Another potential cause of treatment failure is the phenotypical heterogeneity of HCC that results from heterogeneous activation of cancer signaling network . Our study showed a significant variation in signaling transduction protein expression in different patients (see Additional file 5). For example, CDK6 was only expressed in patient A while ERK1/2 was expressed in patient B and C. In this case, if flavopiridal (a pan-CDK inhibitor) is used to treat these patients, the drug may not have been effective in patients B, C and D. On the other hand, when sorafenib (a RAS/ERK pathway inhibitor) is used, the drug may not have been effective for patient A and D. Therefore, assessing the signaling pathway/network before beginning treatment to identify patients that may benefit from targeted therapies may improve the response rate.
Cancer is a complex disease that results from dysregulation of signaling networks caused by the genetic and epigenetic alterations in cells. Therefore, determining the underlying signaling network changes in cancer not only help to understand the molecular mechanism of carcinogenesis but also to identify the signature of signaling networks characteristic for specific cancer types that can be used for diagnosis, prognosis and guidance for targeted therapy. The scientific community will see a significant advancement in cancer signaling network field in the next 5-10 years. Pathologists and laboratory scientists are in the unique position to translate their knowledge of cancer signaling network biology into relevant clinical practice. Conceivably, "-omics" tools, such as DNA and protein microarray, can be successfully used as tissue-based diagnostic and prognostic tools in the future. One ideal model is that cancer patients may visit the oncologist, cytopathologist or radiologist to perform a fine needle aspiration biopsy (FNA) of the tumor. Then, the FNA materials are examined by a cytopathologist for tumor cells and analyzed by a molecular pathologist to reconstruct the signaling network using "-omics tools." This information would be integrated so that the oncologist can use the signaling network information, in addition to clinical and pathological data, to determine the prognosis and customize the treatment (i.e. personalized therapy).
Conflict of interests
The authors declare that they have no competing interests.
This work is supported by the Susan Komen Breast Cancer Foundation and the Department of Defense Breast Cancer Research Program grants to PL
- Laubenbacher R, Hower V, Jarrah A, Torti SV, Shulaev V, Mendes P, Torti FM, Akman S: A systems biology view of cancer. Biochim Biophys Acta 2009, 129–139.
- Thorgeirsson SS, Grisham JW: Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 2002, 31: 339–346. 10.1038/ng0802-339View ArticlePubMed
- Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100: 57–70. 10.1016/S0092-8674(00)81683-9View ArticlePubMed
- Nemunaitis J, Senzer N, Khalil I, Shen Y, Kumar P, Tong A, Kuhn J, Lamont J, Nemunaitis M, Rao D, Zhang YA, Zhou Y, Vorhies J, Maples P, Hill C, Shanahan D: Proof concept for clinical justification of network mapping for personalized cancer therapeutics. Cancer Gene Ther 2007, 14: 686–695. 10.1038/sj.cgt.7701057View ArticlePubMed
- Bejjani BA, Shaffer LG: Application of array-based comparative genomic hybridization to clinical diagnostics. J Mol Diagn 2006, 8: 528–533. 10.2353/jmoldx.2006.060029PubMed CentralView ArticlePubMed
- Hoheisel JD: Microarray technology: beyond transcript profiling and genotype analysis. Nat Rev Genet 2006, 7: 200–210. 10.1038/nrg1809View ArticlePubMed
- Purdom E, Simpson KM, Robinson MD, Conboy JG, Lapuk AV, Speed TP: FIRMA: a method for detection of alternative splicing from exon array data. Bioinformatics 2008, 24: 1707–1714. 10.1093/bioinformatics/btn284PubMed CentralView ArticlePubMed
- Liu CG, Calin GA, Volinia S, Croce CM: MicroRNA expression profiling using microarrays. Nat Protoc 2008, 3: 563–578. 10.1038/nprot.2008.14View ArticlePubMed
- Mao X, Young BD, Lu YJ: The application of single nucleotide polymorphism microarrays in cancer research. Curr Genomics 2007, 8: 219–228. 10.2174/138920207781386924PubMed CentralView ArticlePubMed
- Fullwood MJ, Ruan Y: ChIP-based methods for the identification of long-range chromatin interactions. J Cell Biochem 2009, 107: 30–39. 10.1002/jcb.22116PubMed CentralView ArticlePubMed
- Rauch T, Wang Z, Zhang X, Zhong X, Wu X, Lau SK, Kernstine KH, Riggs AD, Pfeifer GP: Homeobox gene methylation in lung cancer studied by genome-wide analysis with a microarray-based methylated CpG island recovery assay. Proc Natl Acad Sci USA 2007, 104: 5527–5532. 10.1073/pnas.0701059104PubMed CentralView ArticlePubMed
- Brynildsen MP, Wu TY, Jang SS, Liao JC: Biological network mapping and source signal deduction. Bioinformatics 2007, 23: 1783–1791. 10.1093/bioinformatics/btm246View ArticlePubMed
- Fan J, Yang X, Wang W, Wood WH, Becker KG, Gorospe M: Global analysis of stress-regulated mRNA turnover by using cDNA arrays. Proc Natl Acad Sci USA 2002, 99: 10611–10616. 10.1073/pnas.162212399PubMed CentralView ArticlePubMed
- Guerrera IC, Kleiner O: Application of mass spectrometry in proteomics. Biosci Rep 2005, 25: 71–93. 10.1007/s10540-005-2849-xView ArticlePubMed
- Joos T, Bachmann J: Protein microarrays: potentials and limitations. Front Biosci 2009, 14: 4376–4385. 10.2741/3534View Article
- Schweitzer B, Predki P, Snyder M: Microarrays to characterize protein interactions on a whole-proteome scale. Proteomics 2003, 3: 2190–2199. 10.1002/pmic.200300610View ArticlePubMed
- Alhamdani MS, Schroder C, Hoheisel JD: Oncoproteomic profiling with antibody microarrays. Genome Med 2009, 1: 68. 10.1186/gm68PubMed CentralView ArticlePubMed
- Wulfkuhle JD, Aquino JA, Calvert VS, Fishman DA, Coukos G, Liotta LA, Petricoin EF: Signal pathway profiling of ovarian cancer from human tissue specimens using reverse-phase protein microarrays. Proteomics 2003, 3: 2085–2090. 10.1002/pmic.200300591View ArticlePubMed
- Gowan SM, Hardcastle A, Hallsworth AE, Valenti MR, Hunter LJ, de Haven Brandon AK, Garrett MD, Raynaud F, Workman P, Aherne W, Eccles SA: Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assay Drug Dev Technol 2007, 5: 391–401. 10.1089/adt.2006.044View ArticlePubMed
- Kim BK, Lee JW, Park PJ, Shin YS, Lee WY, Lee KA, Ye S, Hyun H, Kang KN, Yeo D, Kim Y, Ohn SY, Noh DY, Kim CW: The multiplex bead array approach to identifying serum biomarkers associated with breast cancer. Breast Cancer Res 2009, 11: R22. 10.1186/bcr2247PubMed CentralView ArticlePubMed
- Ye F, Che Y, McMillen E, Gorski J, Brodman D, Saw D, Jiang B, Zhang DY: The effect of scutellaria baicalensis on the signaling network in HCC cells. Nutr Cancer 2009, 530–537. 10.1080/01635580902803719
- Berglund L, Bjorling E, Oksvold P, Fagerberg L, Asplund A, Szigyarto CA, Persson A, Ottosson J, Wernerus H, Nilsson P, Lundberg E, Sivertsson A, Navani S, Wester K, Kampf C, Hober S, Ponten F, Uhlen M: A genecentric Human Protein Atlas for expression profiles based on antibodies. Mol Cell Proteomics 2008, 7: 2019–2027. 10.1074/mcp.R800013-MCP200View ArticlePubMed
- Ponten F, Jirstrom K, Uhlen M: The Human Protein Atlas--a tool for pathology. J Pathol 2008, 216: 387–393. 10.1002/path.2440View ArticlePubMed
- Zhao Y, Simon R: BRB-ArrayTools Data Archive for Human Cancer Gene Expression: A Unique and Efficient Data Sharing Resource. Cancer Inform 2008, 6: 9–15.PubMed CentralPubMed
- Tusher VG, Tibshirani R, Chu G: Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001, 98: 5116–5121. 10.1073/pnas.091062498PubMed CentralView ArticlePubMed
- Tibshirani R, Hastie T, Narasimhan B, Chu G: Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002, 99: 6567–6572. 10.1073/pnas.082099299PubMed CentralView ArticlePubMed
- Gevaert O, Van Vooren S, De Moor B: A framework for elucidating regulatory networks based on prior information and expression data. Ann N Y Acad Sci 2007, 1115: 240–248. 10.1196/annals.1407.002View ArticlePubMed
- Zhang B, Horvath S: A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol 2005., 4:
- Mootha VK, Lindgren CM, Eriksson KF, Subramanian A, Sihag S, Lehar J, Puigserver P, Carlsson E, Ridderstrale M, Laurila E, Houstis N, Daly MJ, Patterson N, Mesirov JP, Golub TR, Tamayo P, Spiegelman B, Lander ES, Hirschhorn JN, Altshuler D, Groop LC: PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet 2003, 34: 267–273. 10.1038/ng1180View ArticlePubMed
- Lim MS, Carlson ML, Crockett DK, Fillmore GC, Abbott DR, Elenitoba-Johnson OF, Tripp SR, Rassidakis GZ, Medeiros LJ, Szankasi P, Elenitoba-Johnson KS: The proteomic signature of NPM/ALK reveals deregulation of multiple cellular pathways. Blood 2009, 114: 1585–1595. 10.1182/blood-2009-02-204735View ArticlePubMed
- Chen HY, Yu SL, Chen CH, Chang GC, Chen CY, Yuan A, Cheng CL, Wang CH, Terng HJ, Kao SF, Chan WK, Li HN, Liu CC, Singh S, Chen WJ, Chen JJ, Yang PC: A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med 2007, 356: 11–20. 10.1056/NEJMoa060096View ArticlePubMed
- Hu Z, Fan C, Livasy C, He X, Oh DS, Ewend MG, Carey LA, Subramanian S, West R, Ikpatt F, Olopade OI, Rijn M, Perou CM: A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med 2009, 7: 9. 10.1186/1741-7015-7-9PubMed CentralView ArticlePubMed
- Bosch FX, Ribes J, Diaz M, Cleries R: Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004, 127: S5-S16. 10.1053/j.gastro.2004.09.011View ArticlePubMed
- Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008, 48(Suppl 1):S20–37. 10.1016/j.jhep.2008.01.022View ArticlePubMed
- Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M, Talwalkar J, Gores GJ: Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst 2008, 100: 698–711. 10.1093/jnci/djn134View ArticlePubMed
- Chang JT, Carvalho C, Mori S, Bild AH, Gatza ML, Wang Q, Lucas JE, Potti A, Febbo PG, West M, Nevins JR: A genomic strategy to elucidate modules of oncogenic pathway signaling networks. Mol Cell 2009, 34: 104–114. 10.1016/j.molcel.2009.02.030PubMed CentralView ArticlePubMed
- Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D, Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359: 378–390. 10.1056/NEJMoa0708857View ArticlePubMed
- Feo F, Frau M, Tomasi ML, Brozzetti S, Pascale RM: Genetic and epigenetic control of molecular alterations in hepatocellular carcinoma. Exp Biol Med (Maywood) 2009, 234: 726–736. 10.3181/0901-MR-40View Article
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.